linjc16/ctgov huggingface dataset:
Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

Study Overview
=================
Brief Summary
-----------------
Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.

Official Title
-----------------
Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant: a Randomized Clinical Trial

Conditions
-----------------
Liver Transplant Disorder

Intervention / Treatment
-----------------
* Drug: Mannitol
* Other: 0.9% normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with end-stage liver disease who will undergo living donor transplantation. Exclusion Criteria: Patients with a history of portopulmonary hypertension. Hepatopulmonary syndrome. Cirrhotic cardiomyopathy. Hepatorenal syndrome types 1 and 2.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: mannitol group<br> | Drug: Mannitol<br>* During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg<br>|
| Placebo Comparator: control group<br> | Other: 0.9% normal saline<br>* the same amount of 0.9% normal saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mean arterial blood pressure | postreperfusion mean blood pressure | one hour after reperfusion |
Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)

Study Overview
=================
Brief Summary
-----------------
seroPREvalence vis-à-vis SARS-CoV2 and correlation with clinical forms of COVID-19 in patients followed in Pulmonology in the cluster area of the Grand-Est region.

Official Title
-----------------
Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)

Conditions
-----------------
Covid-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Man or woman from 18 years old and without upper age limit Patient followed in pulmonology at Strasbourg University Hospital Patient presenting at least one of the following pathologies: severe persistent asthma (200 patients) chest cancer that is active or has received treatment within a period of less than one year (300 patients) history of lung transplantation performed before the start of the epidemic (02/29/2020) (300 patients) idiopathic or other diffuse interstitial lung disease, sarcoidosis or vasculitis (70 patients) pulmonary arterial hypertension (PAH) (group 1 of the international classification) any cause or chronic thromboembolic PAH (group 4): (60 patients) Severe COPD in the respiratory failure stage (150 patients) Subject affiliated to a social health insurance protection scheme Subject able to understand the objectives of the research Subject having signed an informed consent Exclusion Criteria: Inability to provide informed information about the subject (subject in an emergency situation, difficulty in understanding the subject, etc.) Subject under safeguard of justice Subject under guardianship or guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine and compare the seroprevalence for SARS-CoV2 among patients with respiratory pathologies monitored in Pneumology at the Strasbourg University Hospital, in the cluster zone of the Grand Est. | Carrying out a serological assay of specific antibodies to SARS-CoV-2 | 15 months |
Post-amputation Survival Following Rehabilitation Medium and Long-term Follow up Study, a Retrospective Analysis.

Study Overview
=================
Brief Summary
-----------------
This is a retrospective data analysis of patients who underwent lower limb amputation and rehabilitation and follow up. Investigators analysed their survival outcomes in relation to various comorbidities i. e ischaemic heart disease, renal impairment, vascular interventions.

Detailed Description
-----------------
Inclusion criteria: Patients admitted for major dysvascular lower limb amputation, with complete follow-up record available. Exclusion criteria: Traumatic amputations, minor amputations, i.e. ray and toe amputation, and incomplete follow-up records.

Official Title
-----------------
Prognosticating Outcomes in Stroke, Acquired Brain Injury, Amputee and Other Neurological Impairments

Conditions
-----------------
Amputation

Intervention / Treatment
-----------------
* Other: Follow up for survival


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted for major dysvascular lower limb amputation, with complete follow-up record available. Exclusion criteria: Exclusion Criteria: Traumatic amputations, minor amputations, i.e. ray and toe amputation, and incomplete follow-up records

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Follow up for survival|No intervention, this is an observational study of survival outcomes.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival in relation to time | Survival outcomes were analysed and have been included in the results. | 6 months to 6 years |
Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa

Study Overview
=================
Brief Summary
-----------------
Antepartum hemorrhage is defined as bleeding from or within the female genital tract, occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of pregnancies and is an important cause of perinatal and maternal morbidity and mortality worldwide

Detailed Description
-----------------
There are many tocolytic agents may have a role in conservative management of placenta previa such as magnesium sulfate, calcium channel blockers and β-sympathormimetics. In 2004 Sharma suggests that ritodrine hydrochloride in patients with symptomatic placenta previa tends to prolong the pregnancy and result in an increase in birth weight of the babies without causing any adverse effect on the mother and fetus

Official Title
-----------------
Oral Nifedipine Versus Intravenous Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa: Randomized Controlled Trial.

Conditions
-----------------
Placenta Previa

Intervention / Treatment
-----------------
* Drug: Magnesium Sulfate
* Drug: Nifedipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Estimated gestational age : between 28 weeks and 37 week's gestation Confirmed Placenta previa; either major or minor degrees. Placenta previa with preterm uterine contractions Exclusion Criteria: Severe attack of bleeding requiring an immediate intervention. Fetal heart rates instability or non-reassuring tracing Intrauterine fetal death or major fetal anomalies. If associated with abruptio placentae Patients with known bleeding disorders or on anticoagulant therapy Patients with severe medical disorders as myasthenia gravis documented magnesium toxicity.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Nifidipne<br>received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours | Drug: Nifedipine<br>* received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours<br>|
| Experimental: Magnisum sulphate<br>Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion | Drug: Magnesium Sulfate<br>* Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The duration of prolongation of gestation | measured from the time of enrollment to the time of delivery | 1 month |
Effect of Fentanyl on Main Opioid Receptor (OPRM1) on Human Granulosa Cells.

Study Overview
=================
Brief Summary
-----------------
Opioids is known that produce not only analgesia but also hyperalgesia through activation of central glutaminergic system-GABA. At the same time, recently it was found that the main opioid receptor (OPRM1) is present on human granulosa cells and exogenous opiates and their antagonists can influence granulosa cell vascular endothelial growth factor (VEGF) production via OPRM1, causing ovarian hyperstimulation syndrome. This study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during oocyte retrieval.

Detailed Description
-----------------
The main opioid receptor (OPRM1) is present on human granulosa cells and exogenous opiates and their antagonists can influence granulosa cell vascular endothelial growth factor (VEGF) production via OPRM1, causing ovarian hyperstimulation syndrome. This study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during ultrasound-guided oocyte retrieval. It will be measured the level of cortisone before and 15min after iv administration of fentanyl on blood and on oocyte fluid.

Official Title
-----------------
Effect of Fentanyl on Expression of Main Opioid Receptor (OPRM1) on Human Granulosa Cells During Ultrasound-guided Transvaginal Oocyte Retrieval.

Conditions
-----------------
Stress Reaction, Opioid Use

Intervention / Treatment
-----------------
* Drug: Fentanyl Citrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Physical Status I-III, BMI<30, Exclusion Criteria: Heart failure hepatic failure, hepatitis, drug abuse receiving b blockers receiving b agonists (even bronchodilators)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 32 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fentanyl citrate<br>Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples. | Drug: Fentanyl Citrate<br>* 1γ/Kg fentanyl<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fentanyl | fentanyl on blood sample and oocyte fluid | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cortisone | cortisone on blood sample and oocyte fluid | 15 min |
Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: follow up 3yr recurrence of cardiovascular event death caused by other reasons such as stroke, uremia, blindness and amputation

Official Title
-----------------
Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease

Conditions
-----------------
Type 2 Diabetes, Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Glipizide
* Drug: Metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Coronary heart disease Type 2 diabetes Exclusion Criteria: Severe organ dysfunction, psychopathy, infection, neutropenia Congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy

Ages Eligible for Study
-----------------
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: metformin<br> | Drug: Glipizide<br> <br> |
| Active Comparator: glipizide<br> | Drug: Metformin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New or worsening angina |  |  | 
| new or worsening heart failure |  |  | 
| new critical cardiac arrhythmia |  |  | 
| new peripheral vascular events |  |  |
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

Study Overview
=================
Brief Summary
-----------------
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Detailed Description
-----------------
Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Conditions
-----------------
Lymphomas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy Exclusion Criteria: - to refuse the therapy and need not tolerate the therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease free survival |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mabthera, cytokine induced killer cell
The Potentially Addictive Properties of Soda: A Feasibility Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study to investigate the addictive properties of soda and other sugar sweetened beverages (SBBs) in teenagers aged 13-18 years. It is hypothesized that participants who were regularly consuming sweetened and caffeinated beverages will experience symptoms typical of caffeine withdrawal, such as headache and fatigue, during the SSB withdrawal period.

Official Title
-----------------
The Potentially Addictive Properties of Soda: A Feasibility Study

Conditions
-----------------
Withdrawal Symptoms

Intervention / Treatment
-----------------
* Behavioral: SSB withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Drinks more than 36 ounces of sugar-sweetened beverages per day Speaks fluent English Parent speaks English or Spanish Lives in San Francisco Bay Area Exclusion Criteria: Pregnant or nursing Taking medication to address mental health issues

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SSB withdrawal<br> | Behavioral: SSB withdrawal<br>* During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms of withdrawal | Symptoms of withdrawal during the SSB withdrawal period (days 6-8) will be compared to symptoms of withdrawal during usual consumption period (days 1-3). Three measures are used to assess withdrawal symptoms: Griffiths' withdrawal scale, the relative reinforcing value of soda, and daily check in questions on well-being. | Days 1-3 and days 6-8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in diet | Changes in diet will be assessed by 24-hour dietary recalls and beverage recalls | Days 1-2, 6-8 | 
| Change in impulsivity | Impulsivity will be assessed via the delayed discounting task | Days 1 and 8 | 
| Change in stress | Stress will be assessed via salivary cortisol samples | Days 1 and 8 | 
| Change in preference for soda | Preference for soda will be measured through the Labeled Affective Magnitude Scale (LAMS) and daily check-in questions | Days 1-3, 6-8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Caffeine, Addiction, Withdrawal symptoms, Pediatric, Adolescent, Overweight
FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients

Study Overview
=================
Brief Summary
-----------------
Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness. The cardio-ankle vascular index (CAVI) is a new index of overall stiffness and can estimated the risk of atherosclerosis. Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.

Detailed Description
-----------------
A total of 90 participants who underwent renal transplant were included in the study. The following measures were done and laboratory data were collected. CAVI, Ecchocariogram, Homocysteine, Hs-CRP, Carotid IMT, FGF-21, Medication after renal transplantation, incidence of cardiovascular disease correlation between categorical data was done by using Pearson's correlation test and multiple regression analysis.

Official Title
-----------------
FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients

Conditions
-----------------
Vascular Stiffness

Intervention / Treatment
-----------------
* Other: CAVI and FGF-21


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: renal transplant patients patients for more than 1 month Exclusion Criteria: who had contraindication for CAVI current smoker eGFR <15 ml/min/173 cardiac arrthymia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CAVI and FGF-21<br>renal transplant patients for more than 1 month measured FGF-21 and CAVI | Other: CAVI and FGF-21<br>* FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| association between CAVI and FGF-21 with arterial stiffness in renal transplant patients | cross sectional study | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| association between Hs-CRP,Homocystein with CAVI | cross sectional study | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAVI, FGF-21, arterial stiffness, renal transplant
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

Study Overview
=================
Brief Summary
-----------------
Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

Official Title
-----------------
An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Chronic Neuropathic Pain.

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Pregabalin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia. Must have received study medication under double-blind conditions. Exclusion Criteria: Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pregabalin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and efficacy |  |  |